510 results on '"Cacciola, Emma"'
Search Results
2. Evaluating the Effect of Anagrelide on Fibroblast Growth Factor-2 Levels
3. Are TFPI and β-TG Indicators of Severity in COVID-19?
4. Cellular and molecular mechanisms in COVID-19 coagulopathy: role of inflammation and endotheliopathy
5. Retroperitoneal paraduodenal unicentric Castleman disease: case report and review of the literature
6. Study on the of Anagrelide on Platelet Factor 4 and Vascular Endothelial Growth Factor Levels in Patients with Essential Thrombocythemia
7. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial
8. Autoimmune Diseases and Plasma Cells Dyscrasias: Pathogenetic, Molecular and Prognostic Correlations.
9. Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes
10. Philadelphia chromosome-negative myeloproliferative chronic neoplasms: is clonal hematopoiesis the main determinant of autoimmune and cardio-vascular manifestations?
11. Hemocoagulative post-operative changes after laparoscopic surgery compared to open surgery: the role of lupus anticoagulant
12. 3036 – SPLANCHNIC VEIN THROMBOSIS IN JAK2 V6217F-POSITIVE PATIENTS WITH PRIMARY MYELOFIBROSIS AND LOWER-RISK IPSS
13. P1041: LEUKOCYTOSIS SELECTS A SUBGROUP OF LOW-RISK PV PATIENTS IN WHOM PHLEBOTOMY-ALONE MAY BE INSUFFICIENT
14. Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera
15. Hemocoagulative post-operative changes after laparoscopic surgery compared to open surgery: the role of lupus anticoagulant
16. Is it Still Reasonable to Raise Doubts on Laparoscopic Splenectomy?
17. Ropeginterferon Alfa-2b Versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. Final Results of Low-PV Randomized Phase II Trial
18. 3034 – IMPACT OF ACALABRUTINIB THERAPY ON BRUTON'S TYROSINE KINASE LEVELS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
19. Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera
20. Impact of acalabrutinib therapy on Bruton’s tyrosine kinase levels in patients with chronic lymphocytic leukemia
21. Aumentata espressione piastrinica di FcgammaRIIA e suo potenziale impatto sulla attivazione piastrinica nei pazienti con trombocitemia essenziale. Increased platelet expression of FcgammaRIIA and its potential impact on platelet activation in patients with essential thrombocythemia
22. Hemocoagulative Modifications after Laparoscopic Surgery at Different Pneumoperitoneum Pressure Settings
23. Ropeginterferon Alfa-2b Versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. Final Results of Low-PV Randomized Phase II Trial
24. Thrombosis in Tregs-Induced Thrombocithopenia in Patients with Myelofibrosis
25. Label-Free Enrichment of Circulating Tumor Plasma Cells: Future Potential Applications of Dielectrophoresis in Multiple Myeloma
26. Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms
27. Using stapler in laparoscopic splenectomy does not affect the risk of pancreatic tail injury
28. Laparoscopic surgery: A randomised controlled trial comparing intraoperative hemodynamic parameters and arterial-blood gas changes at two different pneumoperitoneal pressure values
29. Critical appraisal of the European Union Scientific Committee on Health, Environmental and Emerging Risks (SCHEER) Preliminary Opinion on electronic cigarettes
30. Impact of Anti-Endothelial Cell Antibodies (AECAs) in Patients with Polycythemia Vera and Thrombosis
31. Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients
32. TREGs-induced immune thrombotic thrombocytopenia in polycythemia vera
33. Polycyhemia Vera and Immune Thrombogenesis
34. Thrombosis in Tregs-Induced Thrombocytopenia in Patients with Myelofibrosis
35. Are TFPI and beta-TG Indicators of Severity in COVID-19?
36. Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia
37. Vaccine-Induced Thrombotic Thrombocytopenia: Novelty Testing in the Diagnostic Work-up?
38. Cellular and molecular mechanisms in COVID-19 coagulopathy: role of inflammation and endotheliopathy
39. Adverse Outcome in Non-Severe COVID-19: Potential Diagnostic Coagulation Tests
40. Studies on Antiphospholipid Syndrome
41. Coagulopathy in patients with severe COVID-19
42. Study on the Anagrelide on Platelet Factor 4 and Vascular Endothelial Growth Factor Levels in Patients with Essential Thrombocythemia
43. Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms An European Leukemia Net study
44. Quality of life in elderly patients with essential thrombocythaemia. An Italian multicentre study
45. Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation
46. Analysis of common methodological flaws in the highest cited e-cigarette epidemiology research.
47. Are TFPI and β-Tg Indicators of Severity in COVID-19?
48. Ruxolitinib for the treatment of polycythemia vera: response on alternative dose versus standard dose
49. Ropeginterferon alfa-2b vs Phlebotomy in Low-Risk Patients with Polycythemia Vera (Low-PV): A Randomized Phase II Clinical Trial
50. Platelet and coagulative abnormalities in polycythemia vera patients: thrombotic risk
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.